AVXL vs. TCRX, MGTX, TNYA, SOPH, IVVD, AURA, CRBU, JSPR, HUMA, and MGX
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include TScan Therapeutics (TCRX), MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Invivyd (IVVD), Aura Biosciences (AURA), Caribou Biosciences (CRBU), Jasper Therapeutics (JSPR), Humacyte (HUMA), and Metagenomi (MGX). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences (NASDAQ:AVXL) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
Anavex Life Sciences has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 11.6% of Anavex Life Sciences shares are owned by insiders. Comparatively, 8.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, TScan Therapeutics had 15 more articles in the media than Anavex Life Sciences. MarketBeat recorded 21 mentions for TScan Therapeutics and 6 mentions for Anavex Life Sciences. TScan Therapeutics' average media sentiment score of 0.24 beat Anavex Life Sciences' score of 0.02 indicating that TScan Therapeutics is being referred to more favorably in the news media.
Anavex Life Sciences currently has a consensus price target of $40.00, indicating a potential upside of 1,073.02%. TScan Therapeutics has a consensus price target of $12.50, indicating a potential upside of 69.38%. Given Anavex Life Sciences' higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than TScan Therapeutics.
Anavex Life Sciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -423.86%. Anavex Life Sciences' return on equity of -30.32% beat TScan Therapeutics' return on equity.
Anavex Life Sciences has higher earnings, but lower revenue than TScan Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences received 404 more outperform votes than TScan Therapeutics when rated by MarketBeat users. Likewise, 74.08% of users gave Anavex Life Sciences an outperform vote while only 70.37% of users gave TScan Therapeutics an outperform vote.
Summary
Anavex Life Sciences beats TScan Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
